T2357 |
GSK1059615
|
958852-01-2
|
98%
|
|
GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer.
|
T3705 |
GDC0084
|
1382979-44-3
|
98%
|
|
GDC0084 (RG7666) is a PI3K inhibitor with potential antineoplastic activity. GDC0084 (RG7666) specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinas...
|
T2287 |
PIK-75 hydrochloride
|
372196-77-5
|
98%
|
|
PIK-75 hydrochloride (PIK-75 HCl) is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also pote...
|
T5831 |
Selective PI3Kδ Inhibitor 1
|
2088525-31-7
|
98%
|
|
Selective PI3Kδ Inhibitor 1 is a PI3Kδ Inhibitor( IC50 = 0.9 nM).
|
T2461 |
PIK-90
|
677338-12-4
|
98%
|
|
PIK-90, a DNA-PK and PI3K inhibitor, suppresses p110α( IC50=11 nM), p110γ(IC50=18 nM) and DNA-PK(IC50=13 nM) .
|
T6330 |
Linperlisib
|
1702816-75-8
|
98%
|
|
Linperlisib (PI3Kδ-IN-2) is a potent and selective inhibitor of PI3Kδ
|
T6773 |
AZD8186
|
1627494-13-6
|
98%
|
|
AZD8186 is an effective and specific PI3Kβ/δ inhibitor (IC50: 4/12 nM).
|
T7166 |
GNE-493
|
1033735-94-2
|
98%
|
|
GNE-493 is potent, selective, and orally available PI3K and mTOR inhibitor with potential anticancer activity.IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for ...
|
T2P2919 |
(2S,3R,4S)-4-Hydroxyisoleucine
|
55399-93-4
|
98%
|
|
(2S,3R,4S)-4-Hydroxyisoleucine (Hydroxyisoleucine) from fenugreek (Trigonella foenum-graecum) seeds is a potential insulinotropic (anti-diabetic) and anti-obesit...
|
T6251 |
PF-04691502
|
1013101-36-4
|
98%
|
|
PF-04691502 is a potent and selective inhibitor of PI3K and mTOR kinases with antitumor activity.
|
T6319 |
OSI-027
|
936890-98-1
|
98%
|
|
OSI-027 (ASP4786) is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, and more than 100-fold selectivity observed for mTO...
|
T1961 |
Vistusertib
|
1009298-59-2
|
97.94%
|
|
Vistusertib (AZD2014) is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity.
|
T24642 |
YH-306
|
1373764-75-0
|
97.87%
|
|
YH-306 (TRV055 acetate ) is a modulator of the FAK signaling pathway that acts by suppressing colorectal tumor growth and metastasis.
|
T4867 |
Erucic acid
|
112-86-7
|
97.85%
|
|
Increased levels of erucic acid (22:1n9) have been found in the red blood cell membranes of autistic subjects with developmental regression (PMID: 16581239 ). Er...
|
T10804 |
CHMFL-PI3KD-317
|
2244992-76-3
|
97.8%
|
|
CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM, and exhibits over 10-1500 fold selectivity over other clas...
|
T3986 |
SF2523
|
1174428-47-7
|
97.78%
|
|
SF2523 is a highly selective and potent inhibitor.
|
T22377 |
NIBR-17
|
944396-88-7
|
97.67%
|
|
NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
|
T64392 |
PI3K-IN-46
|
304645-61-2
|
97.51%
|
|
PI3K-IN-46 is a specific inhibitor of PI3Kγ.
|
TMA2474 |
δ-Tocotrienol
|
25612-59-3
|
97.38%
|
|
δ-Tocotrienol (Delta-Tocotrienol) is a potential angiogenic inhibitor. δ-Tocotrienol is also a nontoxic activator of mir-34a which can inhibit nonsmall cell lung...
|
T16750 |
Rigosertib
|
592542-59-1
|
97.33%
|
|
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer a...
|